Altimmune Poised For $1B+ Opportunity as MASH Drug Aces Phase IIb
Altimmune’s pemvidutide showed “class-leading signals” in non-invasive assessments and has “potentially best-in-class tolerability,” according to analysts at H.C. Wainwright.
Altimmune Poised For $1B+ Opportunity as MASH Drug Aces Phase IIb Read More »
